Drug Trial Radar · NCT05789082
A Study Evaluating the Safety, Activity, and Pharmacokinetics of Divarasib as a Single Agent or in Combination With Other Anti-Cancer Therapies in Participants With Previously Untreated Advanced or Metastatic Non-Small Cell Lung Cancer With a KRAS G12C Mutation
Last checked: Nov 19, 2026Latest source record: Nov 5, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Recruiting
Enrollment
320
Planned (sponsor's estimate)
Start
Jun 20, 2023
Primary completion
Jan 29, 2032
Study completion Jan 29, 2032
Sponsor
- Lead sponsor
- Hoffmann-La RocheRoche (Genentech) (RHHBY)
- Sponsor type
- Industry
- First posted
- Mar 29, 2023
Design
- Study type
- Interventional
- Phase
- Phase 1 / Phase 2
- Allocation
- Randomized
- Model
- Parallel
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The purpose of this study is to evaluate the safety, pharmacokinetics (PK), and activity of single-agent divarasib or combined with other anti-cancer therapies in participants with previously untreated, advanced or metastatic non-small cell lung cancer (NSCLC).
Conditions
- Non-Small Cell Lung Cancer
Interventions
DivarasibDrug
Participants will receive divarasib orally (PO), QD on days 1-21 of each 21-day cycle.
PembrolizumabDrug
Participants will receive a 200 mg IV infusion of pembrolizumab Q3W on Day 1 of each 21-day cycle.
CarboplatinDrug
Participants will receive IV carboplatin Q3W for four 21-day cycles.
CisplatinDrug
Participants will receive IV cisplatin Q3W for four 21-day cycles.
PemetrexedDrug
Participants will receive IV pemetrexed Q3W.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Percentage of Participants with Adverse Events (AEs)Time frame: Baseline until 60 days after the final dose of study treatment or until initiation of another anti-cancer therapy, whichever occurs first (up to approximately 5 years)
Locations
71 sites in 18 countries. Site status is shown where the registry gives one.
City of Hope National Medical Center
Duarte, California · Withdrawn
City of Hope - Seacliff
Huntington Beach, California · Withdrawn
City of Hope at Irvine Lennar
Irvine, California · Withdrawn
UCSD Moores Cancer Center
La Jolla, California · Withdrawn
City of Hope - Long Beach Elm
Long Beach, California · Withdrawn
Yale Cancer Center
New Haven, Connecticut · Recruiting
Florida Cancer Specialists - SOUTH - SCRI - PPDS
Fort Myers, Florida · Recruiting
Florida Cancer Specialists - NORTH - SCRI - PPDS
St. Petersburg, Florida · Recruiting
Florida Cancer Specialists - EAST - SCRI - PPDS
West Palm Beach, Florida · Recruiting
NYU Langone Hospital - Long Island
Mineola, New York · Recruiting
NYU Cancer Center
New York, New York · Recruiting
Mount SInai Medical Center
New York, New York · Recruiting
Montefiore Medical Center - Montefiore Medical Park
The Bronx, New York · Recruiting
MD Anderson Cancer Center
Houston, Texas · Recruiting
Oncology & Hematology Associates of Southwest Virginia, Inc
Blacksburg, Virginia · Recruiting
Virginia Oncology Associates
Norfolk, Virginia · Recruiting
Hospital Britanico
Buenos Aires, Argentina · Recruiting
Clinica Adventista Belgrano
Ciudad Autonoma Buenos Aires, Argentina · Recruiting
Centro Oncologico Riojano Integral (CORI)
La Rioja, Argentina · Recruiting
Concord Repatriation General Hospital
Concord, New South Wales, Australia · Completed
Peter MacCallum Cancer Centre
Melbourne, Victoria, Australia · Recruiting
Alfred Health
Melbourne, Victoria, Australia · Recruiting
Cliniques Universitaires St-Luc
Brussels, Belgium · Recruiting
Jessa Zkh (Campus Virga Jesse)
Hasselt, Belgium · Recruiting
Clinique Ste-Elisabeth
Namur, Belgium · Recruiting
AZ Delta (Campus Rumbeke)
Roeselare, Belgium · Recruiting
Hospital de Cancer de Barretos
Barretos, São Paulo, Brazil · Recruiting
Instituto do Cancer do Estado de Sao Paulo - ICESP
São Paulo, São Paulo, Brazil · Recruiting
Ottawa Hospital Regional Cancer Centre
Ottawa, Ontario, Canada · Recruiting
Princess Margaret Cancer Center
Toronto, Ontario, Canada · Active not recruiting
Jewish General Hospital
Montreal, Quebec, Canada · Recruiting
Hunan Cancer Hospital
Changsha, China · Recruiting
Harbin Medical University Cancer Hospital
Harbin, China · Recruiting
Shanghai Pulmonary Hospital
Shanghai, China · Recruiting
Rambam Medical Center
Haifa, Israel · Recruiting
Rabin MC
Petah Tikva, Israel · Recruiting
Tel Aviv Sourasky Medical Ctr
Tel Aviv, Israel · Recruiting
Istituto Nazionale Tumori Fondazione G. Pascale
Naples, Campania, Italy · Withdrawn
Policlinico Universitario Agostino Gemelli IRCCS
Rome, Lazio, Italy · Active not recruiting
Irccs Istituto Nazionale Dei Tumori (Int)
Milan, Lombardy, Italy · Recruiting
Showing 40 of 71 sites, US sites first. The full list is on the registry record.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.